Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

for
Solid Tumor Cancer
Location: Santa Monica CA
Sponsor: Sarcoma Oncology Research Center, LLC

Sex: All

Age: 18+

Code: NCT07671534

Phase 2, Recruiting
Active & Responsive

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Location: New York NY, Fairfax VA, Nashville TN, Houston TX,
Sponsor: NEOK Bio, Inc.

Sex: All

Age: 18+

Code: NCT07612176

Phase 1, Recruiting
Active & Responsive

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

for
Small-cell Lung Cancer, Neuroendocrine Carcinomas,
Location: New York NY, Philadelphia PA, Fairfax VA, Orlando FL,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07174583

Phase 1, Phase 2, Recruiting
Active & Responsive

ARC101 in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Montreal, Toronto, Vancouver
Sponsor: Third Arc Bio

Sex: All

Age: 18+

Code: NCT06672185

Phase 1, Recruiting
Active & Responsive

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

for
Metastatic Solid Tumors
Location: Nashville TN, Houston TX, Irving TX, San Antonio TX,
Sponsor: Erasca, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07021898

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for
Solid Tumor Malignancies
Location: New Haven CT, Fairfax VA, Jacksonville FL, Sarasota FL,
Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT06994806

Phase 1, Recruiting
Active & Responsive

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

for
Breast Cancer, Endometrial Cancer, Ovarian Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Cleveland OH,
Sponsor: Terremoto Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07109726

Phase 1, Phase 2, Recruiting
Active & Responsive

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

for
Solid Tumors, Hematologic Malignancies
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 0+

Code: NCT02457962

Recruiting
Active & Responsive

The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care

for
Cancer, Cancer Comorbidities
Location: Flint MI, Houston TX
Sponsor: National Minority Quality Forum

Sex: All

Age: 35+

Code: NCT07461493

Recruiting
Active & Responsive

Efficacy of Point Of Service Testing in MBC

for
Metastatic Cancer, Breast Cancer
Location: Kansas City KS
Sponsor: University of Kansas Medical Center

Sex: All

Age: 18+

Code: NCT03983577

Recruiting
Active & Responsive

CREATE: Art for Children With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 8 - 13

Code: NCT06342453

Recruiting
Active & Responsive

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

for
Solid Tumor
Location: Dallas TX, Scottsdale AZ, Portland OR, El Segundo CA,
Sponsor: Alyssum Therapeutics

Sex: All

Age: 18+

Code: NCT06234098

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

for
Advanced Solid Tumors
Location: Moncton, Hackensack NJ, Fairfax VA, Kingston, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05067283

Phase 1, Recruiting
Active & Responsive

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Boston MA, New York NY, Hackensack NJ,
Sponsor: ModernaTX, Inc.

Sex: All

Age: 12+

Code: NCT05533697

Phase 1, Phase 2, Recruiting
Active & Responsive

Activating Cancer Communities Through an Exercise Strategy for Survivors

for
Cancer
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: All

Age: 18+

Code: NCT03599843

Recruiting
Active & Responsive

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis,
Location: Boston MA, New Haven CT, New York NY,
Sponsor: Institut de Recherches Internationales Servier

Sex: All

Age: 18+

Code: NCT05786924

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

for
Metastatic Solid Tumors
Location: Boston MA, New York NY, Fairfax VA, Toronto, Tampa FL,
Sponsor: Erasca, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06983743

Phase 1, Recruiting
Active & Responsive

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Jacksonville FL, Tampa FL, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06353191

Recruiting
Active & ResponsiveNew

A KRAS Inhibitor in Participants With Advanced Solid Tumors

for
Metastatic Colorectal Cancer (CRC),
Location: Fairfax VA
Sponsor: Ensem Therapeutics

Sex: All

Age: 18+

Code: NCT07912593

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Oklahoma City OK
Sponsor: University of Oklahoma

Sex: All

Age: 18+

Code: NCT07829185

Phase 1, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial